NASDAQ:IXHL

Incannex Healthcare Q1 2027 Earnings Results & Report

Incannex Healthcare logo
$1.93 -0.04 (-2.03%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$1.93 0.00 (-0.05%)
As of 11/16/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Incannex Healthcare beat analyst earnings expectations in its Q1 2027 results, released November 12, 2026. The company reported EPS of -$0.15 versus the -$0.44 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2027
Time
Before Market Opens
Conference Call
7:00 AM ET

Incannex Healthcare EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.44
Beat/Miss
Beat by +$0.29
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 6 quarters

Incannex Healthcare Revenue Results

Actual Revenue
N/A
Expected Revenue
$10 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Incannex Healthcare Q1 2027 Earnings FAQ

Incannex Healthcare (NASDAQ:IXHL) reported earnings of -$0.15 per share for Q1 2027, beating the consensus estimate of -$0.44. The report was announced on Thursday, November 12, 2026.

Incannex Healthcare Earnings Headlines

Incannex Healthcare (IXHL) Expected to Release Earnings on Friday
Incannex Healthcare Inc. (IXHL)
Your Copy is on Hold (Claim it now)
James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.tc pixel
Incannex Healthcare Inc IXHL
See More Incannex Healthcare Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Incannex Healthcare? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Incannex Healthcare and other key companies, straight to your email.

About Incannex Healthcare

Incannex Healthcare (NASDAQ:IXHL) is a clinical-stage biopharmaceutical company developing investigational medicines, including cannabinoid-based combination therapies and psychedelic-assisted treatments. Its research focuses on conditions with significant unmet medical needs; its products are in development and are not established as approved treatments.

The company’s pipeline has included IHL-42X, a combination of dronabinol and acetazolamide being studied for obstructive sleep apnea, as well as programs targeting inflammatory conditions and traumatic brain injury. Incannex has also pursued research into psychedelic-assisted therapies for mental health conditions.

Incannex is an Australian-origin company whose shares trade on Nasdaq under the symbol IXHL. Its work is primarily focused on drug research and development rather than the sale of marketed medicines.

View Incannex Healthcare Profile